Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.07, 8.01 · 8-K

Canton Strategic Holdings, Inc.

CNTNNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders · Other Events

Item 5.07 Submission of Matters to a Vote of Security Holders On July 13, 2026, Canton Strategic Holdings, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual Meeting ”).…

Filed Jul 17, 2026Accepted Jul 17, 2026, 8:30 AM EDTCIK 1861657Accession 0001493152-26-033664
Share

Company context

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.

Current securities

Historical securities (1)

Recent company filings

  1. Regulation FD DisclosureOct 29, 2026
  2. 4 filingOct 27, 2026
  3. 4 filingOct 27, 2026
  4. 4 filingOct 27, 2026
  5. Results of Operations and Financial ConditionAug 14, 2026

Registered securities in this filing

CANTON STRATEGIC HOLDINGS, INC. · 8-K · Filed 2026-07-17

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, $0.0001 par value

Symbol
CNTN
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-07-13

Dimensions: Not supplied

Accession 000149315226033664 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.07, 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders On July 13, 2026, Canton Strategic Holdings, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual Meeting ”). At the close of business on June 16, 2026, the record date for the Annual Meeting (the “ Record Date ”), there were 77,122,584 shares of the Company’s Common Stock, par value $0.0001 per share (the “ Common Stock ”) issued and outstanding. A total of 25,792,741 shares of Common Stock, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on June 25, 2026, are as follows: Proposal 1. All of the seven (7) nominees for director were elected to serve until the 2027 annual meeting of stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the seven (7) directors was as follows: Directors For Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────────────── Mark Wendland 25,781,710 11,031 0 Clay Kahler 25,490,487 302,254 0 Jill E. Sommers 25,782,510 10,231 0 William Wiley 25,781,103 11,638 0 Sean Galvin 25,756,323 36,418 0 Pamela L. Carter 25,782,586 10,155 0 Rishi Nangalia 25,782,393 10,348 0 Proposal 2. The appointment of Rosenberg Rich Baker Berman P.A., as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain ──────────────────────────────────────── 25,780,986 3,980 7,775
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On July 15, 2026, during a special meeting of the Board of Directors, the Board elected the following directors to serve on its committees: Audit Committee: Sean Galvin (as the Chair), Jill E. Sommers and Pamela L. Carter. Compensation Committee: William Wiley (as the Chair), Clay Kahler and Rishi Nangalia. Nominating and Governance Committee: Jill E. Sommers (as the Chair), William Wiley and Pamela L. Carter.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.